Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health care

Nuclear Medicine Review

Volumn 12, Issue 1, 2009, Pages 1-13

  Basu, Sandip ^a,b   Alavi, Abass ^a,b  

^a TATA MEMORIAL HOSPITAL   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18 F fluorodeoxyglucose; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEALTH CARE; HUMAN; MEDICAL PRACTICE; NEUROLOGIC DISEASE; OSTEOMYELITIS; POSITRON EMISSION TOMOGRAPHY; REVIEW;

DELIVERY OF HEALTH CARE; FORECASTING; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68349103025     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Schaner EG, Chang AE, Doppman JL, Conkle DM, Flye MW, Rosenberg SA. Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol 1978; 131: 51-54.
2. Vanel D, Henry-Amar M, Lumbroso J et al. Pulmonary evaluation of patients with osteosarcoma: roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. AJR Am J Roentgenol 1984; 143: 519-523. (Pubitemid 14066649)
3. Muhm JR, Brown LR, Crowe JK, Sheedy II PF, Hattery RR, Stephens DH. Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules. AJR Am J Roentgenol 1978; 131: 981-984.
4. Crim JR, Cracchiolo A, Bassett LW, Seeger LL, Soma CA, Chatelaine A. Magnetic resonance imaging of the hindfoot. Foot Ankle 1989; 10: 1-7.
5. Hilpert PL, Friedman AC, Radecki PD et al. MRI of hemorrhagic renal cysts in polycystic kidney disease. AJR Am J Roentgenol 1986; 146: 1167-1172.
6. Semelka RC, Shoenut JP, Ascher SM et al. Solitary hepatic metastasis: comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences. J Magn Reson Imaging 1994; 4: 319-323.
7. Stark DD, Wittenberg J, Butch RJ, Ferrucci Jr JT. Hepatic metastases: randomized, controlled comparison of detection with MR imaging and CT. Radiology 1987; 165: 399-406. (Pubitemid 17156871)
8. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002; 53: 89-112. (Pubitemid 34177873)
9. Blasberg RG, Gelovani J. Molecular-genetic imaging: a nuclear medicine-based perspective. Mol Imaging 2002; 1: 280-300.
10. Johnson GA, Cofer GP, Fubara B, Gewalt SL, Hedlund LW, Maronpot RR. Magnetic resonance histology for morphologic phenotyping. J Magn Reson Imaging 2002; 16: 423-429. (Pubitemid 35167877)
11. Calautti C, Baron JC. Functional neuroimaging studies of motor recovery after stroke in adults: a review. Stroke 2003; 34: 1553-1566. (Pubitemid 36693533)
12. Hennig J, Speck O, Koch MA, Weiller C. Functional magnetic resonance imaging: a review of methodological aspects and clinical applications. J Magn Reson Imaging 2003; 18: 1-15. (Pubitemid 36791263)
13. Cohen M, Bookheimer S. Localization of brain function using magnetic resonance imaging. Tech Neurosci 1994; 17: 268-277.
14. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003; 170: S69-S75 [discussion, S75-S76]. (Pubitemid 37413946)
15. Rovaris M, Rocca MA, Filippi M. Magnetic resonance-based techniques for the study and management of multiple sclerosis. Br Med Bull 2003; 65: 133-144. (Pubitemid 36406462)
16. Kantarci K, Jack Jr CR. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 2003; 13: 197-209. (Pubitemid 36791507)
17. Bremer C, Ntziachristos V, Weissleder R. Optical based molecular imaging: contrast agents and potential medical applications. Eur Radiol 2003; 13: 231-243 (Pubitemid 36798598)
18. Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA 2000; 97: 2767-2772. (Pubitemid 30159246)
19. Bremer C, Tung CH, Bogdanov Jr A, Weissleder R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 2002; 222: 814-818. (Pubitemid 34218157)
20. Kirkpatrick PJ, Lam J, Al-Rawi P, Smielewski P, Czosnyka M. Defining thresholds for critical ischemia by using near-infrared spectroscopy in the adult brain. J Neurosurg 1998; 89: 389-394. (Pubitemid 28405252)
21. Miyai I, Yagura H, Hatakenaka M, Oda I, Konishi I, Kubota K. Longitudinal optical imaging study for locomotor recovery after stroke. Stroke 2003; 34: 2866-2870. (Pubitemid 37517758)
22. Wunderbaldinger P, Turetschek K, Bremer C. Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe. Eur Radiol 2003; 13: 2206-2211. (Pubitemid 37080758)
23. Marten K, Bremer C, Khazaie K et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 2002; 122: 406-414. (Pubitemid 34116992)
24. Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998; 25: 788-792. (Pubitemid 28377043)
25. Alavi A, Reivich M. The conception of FDG-PET imaging. Semin Nucl Med 2003; 32: 58-81.
26. Alavi A, Hirsch LJ. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography: evolution over the past 2 decades. Semin Nucl Med 1991; 21: 58-81.
27. Blasberg R. PET imaging of gene expression. Eur J Cancer 2002; 38: 2137-2146.
28. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Assays for non-invasive imaging of reporter gene expression. Nucl Med Biol 1999; 26: 481-490.
29. Cherry SR. Fundamentals of positron emission tomography and applications in preclinical drug development. J Clin Pharmacol 2001; 41: 482-491.
30. Vaalburg W, Hendrikse NH, de Vries EF. Drug development, radiolabelled drugs and PET. Ann Med 1999; 31: 432-437. (Pubitemid 30055114)
31. Bachelard HS, Thompson MF, Polkey CE. Kinetic properties of hexokinase in resected temporal lobes of patients with drug-resistant epilepsy. Epilepsia 1975; 16: 431-437.
32. Newberg A, Alavi A, Reivich M. Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med 2002; 32: 13-34. (Pubitemid 34112940)
33. Engel Jr J, Kuhl DE, Phelps ME, Rausch R, Nuwer M. Local cerebral metabolism during partial seizures. Neurology 1983; 33: 400-413.
34. Theodore WH, Newmark ME, Sato S et al. [18F]Fluorodeoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol 1983; 14: 429-437.
35. Barrington SF, Koutroumanidis M, Agathonikou A et al. Clinical value of "'ictal'" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 1998; 39: 753-766.
36. Moran NF, Lemieux L, Kitchen ND, Fish DR, Shorvon SD. Extrahippocampal temporal lobe atrophy in temporal lobe epilepsy and mesial temporal sclerosis. Brain 2001; 124: 167-175. (Pubitemid 32055998)
37. Kobayashi E, D'Agostino MD, Lopes-Cendes I, Berkovic SF, Li ML, Andermann E, et al. Hippocampal atrophy and T2-weighted signal changes in familial mesial temporal lobe epilepsy. Neurology 2003; 60: 405-409. (Pubitemid 36188234)
38. Meyer PT, Cortes-Blanco A, Pourdehnad M, Levy-Reis I, Desiderio L, Jang S, et al. Inter-modality comparisons of seizure focus lateralization in complex partial seizures. Eur J Nucl Med 2001; 28: 1529-1540. (Pubitemid 32938403)
39. Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 1999; 52: 700-708. (Pubitemid 29120170)
40. Morris JC, Cyrus PA, Orazem J et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease [comment]. Neurology 1998; 50: 1222-1230. (Pubitemid 28240332)
41. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271: 985-991.
42. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group [comment]. Neurology 1998; 50: 136-145.
43. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [comment] [erratum appears in BMJ 2001; 16; 322(7300): 1456]. BMJ 1999; 318: 633-638.
44. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F] fluorodeoxyglucose method. Ann Neurol 1984; 15: 419-424.
45. Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002; 16: 515-525. (Pubitemid 36205668)
46. Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, Reivich M. Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med 1986; 16: 2-34.
47. Salmon E, Sadzot B, Maquet P et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 1994; 35: 391-398. (Pubitemid 24079962)
48. Van Heertum RL, Tikofsky RS. Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 2003; 33: 77-85. (Pubitemid 36169395)
49. Silverman DH, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286: 2120-2127.
50. Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002; 17: 302-316.
51. Alavi A, Clark C, Fazekas F. Cerebral ischemia and Alzheimer's disease: critical role of PET and implications for therapeutic intervention. J Nucl Med 1998; 39: 1363-1365. (Pubitemid 28373557)
52. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimers disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993; 34: 1681-1687. (Pubitemid 23295377)
53. Davis MR, Votaw JR, Bremner JD et al. Initial human PET imaging studies with the dopamine transporter ligand 18FFECNT. J Nucl Med 2003; 44: 855-861.
54. Vingerhoets FJ, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine-18 -6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med 1996; 37: 421-426. (Pubitemid 26094264)
55. Huang WS, Chiang YH, Lin JC, Chou YH, Cheng CY, Liu RS. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients. J Nucl Med 2003; 44: 999-1005. (Pubitemid 39663372)
56. Alavi A, Newberg AB. Metabolic consequences of acute brain trauma: is there a role for PET? J Nucl Med 1996; 37: 1170-1172.
57. Newberg AB, Alavi A. Neuroimaging in patients with head injury. Semin Nucl Med 2003; 33: 136-147.
58. Newberg A, Cotter A, Udeshi M, Alavi A, Clark C.A metabolic imaging severity rating scale for the assessment of cognitive impairment. Clin Nucl Med 2003; 28: 565-570. (Pubitemid 38281921)
59. Mazziotta JC, Phelps ME, Pahl JJ et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987; 316: 357-362. (Pubitemid 17034259)
60. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-434.
61. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease. Psychiatry Res 1989; 29: 361-362. (Pubitemid 19265393)
62. Hustinx R, Benard F, Alavi A. Whole-body FDGPET imaging in the management of patients with cancer. Semin Nucl Med 2002; 32: 35-46. (Pubitemid 34112941)
63. Wahl RL, Hawkins RA, Larson SM et al. Proceedings of a National Cancer Institute workshop: PET in oncology - a clinical research agenda. Radiology 1994; 193: 604-606.
64. Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674. (Pubitemid 27023063)
65. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150-185.
66. Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 1996; 23: 204-206. (Pubitemid 26057000)
67. Albes JM, Lietzenmayer R, Schott U, Schulen E, Wehrmann M, Ziemer G. Improvement of non-small cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg 1999; 47: 42-47. (Pubitemid 29157010)
68. Coleman RE. PET in lung cancer. J Nucl Med 1999; 40: 814-820.
69. Wahl RL. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 2001; 36: 250-260. (Pubitemid 32701400)
70. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med-Commun 2000; 21: 793-798.
71. Bohuslavizki KH, Klutmann S, Sonnemann U et al. [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region]. Laryngorhinootologie 1999; 78: 445-449.
72. Bohuslavizki KH, Klutmann S, Kroger S et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-822. (Pubitemid 30266025)
73. Braams JW, Pruim J, Kole AC et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26: 112-115. (Pubitemid 127357227)
74. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999; 35: 1076-1082. (Pubitemid 29339190)
75. Kole AC, Nieweg OE, Pruim J et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82: 1160-1166. (Pubitemid 28136532)
76. Hustinx R, Smith RJ, Benard F et al. Dual time pointfluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26: 1345-1348. (Pubitemid 29467031)
77. Keyes JW JR, Watson Jr NE, Williams III DW, Greven KM, McGuirt WF. FDG PET in head and neck cancer. AJR Am J Roentgenol 1997; 169: 1663-1669. (Pubitemid 127469801)
78. Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-25. (Pubitemid 36075491)
79. Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38: 1196-1201. (Pubitemid 27332611)
80. Flamen P, Hoekstra OS, Homans F et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001; 37: 862-869. (Pubitemid 32323964)
81. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer [comment]. Ann Surg 1998; 227: 319-323. (Pubitemid 28131010)
82. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943-947. (Pubitemid 23244732)
83. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996; 78: 2216-2222. (Pubitemid 26367617)
84. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-728. (Pubitemid 28377035)
85. Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065. (Pubitemid 32565444)
86. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-708. (Pubitemid 26085512)
87. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480. (Pubitemid 34879334)
88. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J Nucl Med 1994; 35: 104-112. (Pubitemid 24018451)
89. Schuster DP, Kozlowski J, Hogue L, Ferkol TW. Imaging lung inflammation in a murine model of Pseudomonas infection: a positron emission tomography study. Exp Lung Res 2003; 29: 45-57. (Pubitemid 36021043)
90. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med. 2009; 39: 36-51.
91. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009; 39: 124-145.
92. Manthey N, Reinhard P, Moog F, Knesewitsch P, Hahn K, Tatsch K. The use of [18 F]Fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun 2002; 23: 645-653.
93. Zhuang H, Duarte PS, Pourdehnad M et al. The promising role of 18FFDG PET in detecting infected lower limb prosthesis implants. J Nucl Med 2001; 42: 44-48. (Pubitemid 32104776)
94. Vanquickenborne B, Maes A, Nuyts J et al. The value of (18)FDGPET for the detection of infected hip prosthesis. Eur J Nucl Med Mol Imaging 2003; 30: 705-715.
95. Zhuang H, Duarte PS, Pourdehand M, Shnier D, Alavi A. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med 2000; 25: 281-284. (Pubitemid 30173879)
96. Guhlmann A, Brecht-Krauss D, Suger G et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med 1998; 39: 2145-2152. (Pubitemid 29001808)
97. Kalicke T, Schmitz A, Risse JH et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med 2000; 27: 524-528. (Pubitemid 30262617)
98. Bakheet SMB, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J. F-18FDG uptake in breast infection and inflammation. Clin Nucl Med 2000; 25: 100-103. (Pubitemid 30068866)
99. Kao CH. Ring-like FDG uptake in acute cholecystitis. Clin Nucl Med 2003; 28: 162-163.
100. Krupnick AS, Lombardi JV, Engels FH et al. 18-fluorodeoxyglucose positron emission tomography as a novel imaging tool for the diagnosis of aortoenteric fistula and aortic graft infection-a case report. Vasc Endovasc Surg 2003; 37: 363-366.
101. Yu JQ, Kung JW, Potenta S, Xiu Y, Alavi A, ZhuangH. Chronic cholecystitis detected by FDG-PET. Clin Nucl Med 2004; 29: 496-497.
102. Blockmans D, Knockaert D, Maes A et al. Clinical value of [(18)F]fluorodeoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32: 191-196.
103. Meller J, Altenvoerde G, Munzel U et al. Fever of unknown origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med 2000; 27: 1617-1625. (Pubitemid 30812517)
104. Lorenzen J, Buchert R, Bohuslavizki KH. Value of FDG PET in patients with fever of unknown origin. Nucl Med Commun 2001; 22: 779-783. (Pubitemid 32613439)
105. Bleeker-Rovers CP, de Kleijn E, Corstens FHM, van der Meer JWM, Oyen WJG. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 2004; 31: 29-37.
106. Neurath MF, Vehling D, Schunk K et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002; 97: 1978-1985. (Pubitemid 34906846)
107. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med 1994; 35: 1650-1652.
108. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
109. Ludwig V, Fordice S, Lamar R, Martin WH, Delbeke D. Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med 2003; 28: 176-179. (Pubitemid 38281972)
110. Yasuda S, Shohtsu A, Ide M et al. High fluorine-18 labeled deoxyglucose uptake in sarcoidosis. Clin Nucl Med 1996; 21: 983-984. (Pubitemid 26412233)
111. Polisson RP, Schoenberg OI, Fischman A et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 819-825.
112. Hara M, Goodman PC, Leder RA FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr 1999; 23: 16-18. (Pubitemid 29095460)
113. deKemp R, Ruddy T, Hewitt T, Dalipaj M, Beanlands R. Detection of serial changes in absolute myocardial perfusion with 82Rb PET. J Nucl Med 2000; 41: 1426-1435.
114. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 2002; 32: 70-76. (Pubitemid 34112944)
115. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18Ffluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 2001; 31: 28-49.
116. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18] fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998; 209: 253-258.
117. van Eijkeren ME, Thierens H, Seuntjens J, Goethals P, Lemahieu I, Strijckmans K. Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck. Acta Oncol 1996; 35: 737-741. (Pubitemid 26366734)
118. Vander Borght T, Labar D, Pauwels S, Lambotte L. Production of [2-11C]thymidine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum [A] 1991; 42: 103-104.
119. Barthel H, Cleij MC, Collingridge DR et al. 30-deoxy-30-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-3798. (Pubitemid 36793068)
120. Buck AK, Schirrmeister H, Hetzel M et al. 3-deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62: 3331-3334.
121. Wagner M, Seitz U, Buck A et al. 30-[18F]fluoro-30-deoxythymidine([18F]- FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681-2687. (Pubitemid 36605213)
122. Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-1336.
123. Dittmann H, Dohmen BM, Paulsen F et al. F-18 FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30: 1407-1412. (Pubitemid 37247960)
124. Cobben DCP, Elsinga PH, Suurmeijer AJH et al. Detection and grading of soft tissue sarcomas of the extremities with F-18-30-fluoro-30-deoxy-L- thymidine. Clin Cancer Res 2004; 10: 1685-1690.
125. Halter G, Buck AK, Schirrmeister H et al. F-18 3-deoxy-30-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-F-18-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovas Surg 2004; 127: 1093-1099.
126. Koh WJ, Bergman KS, Rasey JS et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-398.
127. Nunn A, Under K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-280.
128. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-1160. (Pubitemid 27339632)
129. Evans SM, Kachur AV, Shiue CY et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000; 41: 327-336.
130. Dolbier Jr WR, Li AR, Koch CJ, Shiue CY, Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001; 54: 73-80. (Pubitemid 32073200)
131. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002; 16: 352-361. (Pubitemid 35167871)
132. Eliceiri BP, Cheresh DA. The role of alpha V integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-1230.
133. Cheresh DA. Structure, function and biological properties of integrin alphaVbeta3 on human melanoma cells. Cancer Metastasis Rev 1991; 10: 3-10.
134. Haubner R, Wester HJ, Weber WA et al. Noninvasive imaging of alpha(V)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 1781-1785.
135. Haubner R, Wester HJ, Burkhart F et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42: 326-336. (Pubitemid 32150525)
136. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918-3928.
137. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463. (Pubitemid 34525730)
138. Anderson CJ, Connett JM, Schwarz SW et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992; 33: 1685-1691.
139. Hofmann M, Maecke H, Borner R et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
140. Henze M, Schuhmacher J, Hipp P et al. PET imaging of somatostatin receptors using. J Nucl Med 2001; 42: 1053-1056.
141. Ogawa T, Shishido F, Kanno I et al. Cerebral glioma: evaluation with methionine PET [comment]. Radiology 1993; 186: 45-53. (Pubitemid 23005465)
142. Wester HJ, Schottelius M, Scheidhauer K et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003; 30: 117-122. (Pubitemid 36692901)
143. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-445. (Pubitemid 32207394)
144. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39: 990-995. (Pubitemid 28270113)
145. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27: 1415-1419. (Pubitemid 30680634)
146. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-280.
147. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med 2003; 44: 556-558. (Pubitemid 39663422)
148. Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 181-186. (Pubitemid 34151040)
149. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16-alpha-[18F]fluoro-17-beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systematic therapy. Clin Cancer Res 1996; 2: 933-939. (Pubitemid 26198463)
150. Dehdashti F, Mortimer JE, Siegel BA et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
151. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-693. (Pubitemid 37328919)
152. Zhuang H, Pourdehnad M, Lambright ES et al. Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412-1417. (Pubitemid 32852620)
153. Conrad GR, Sinha P. Narrow time-window dual-point F-18-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun 2003; 24: 1129-1137. (Pubitemid 39625398)
154. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med 2008; 49: 17N-21N, 37N.
155. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin North Am 2004; 42: 983-1001.
156. Basu S, Kumar R, Rubello D, Fanti S, Alavi A. PET Imaging in Neuroendocrine tumors: Current status and future prospects. Minerva Endocrinol 2008; 33: 257-275.
157. Basu S, Torigian D, Alavi A. The role of modern molecular imaging techniques in gastroenterology. Gastroenterology 2008; 135: 1055-1061.